Characterization of gut microbiome composition in T2D patients under SGLT2i and GLP1RA treatment

Abstract

Type 2 Diabetes (T2D) is a globally recognized health concern that has garnered significant research attention. This thesis work focuses on gut microbiome analysis in T2D patients who start taking two medications antidiabetic drugs: Empaglifrozin (SGLT2i) and Semaglutide (GLP1RA). Microbiome composition was analyzed using 16S rRNA sequencing. The research aims to enhance our understanding of how the gut microbiome is related to SGLT2/GLP1 drug intake, potentially leading to the development of personalized treatment approaches for improved patient outcomes.